Why Peptide Delivery Is a Multibarrier Research Problem

Most peptides are larger and more polar than molecules that diffuse readily through lipid bilayers. Epithelial tight junctions, mucus, efflux systems, and intracellular trafficking add further barriers. Uptake observed in an isolated cell system may depend on concentration, membrane damage, transporter expression, or endosomal trapping. Evidence for entry into cells is distinct from evidence that an intact, active peptide reaches a specific intracellular target in an organism.

Once present in circulation or tissue, peptides can bind plasma proteins, partition into extracellular spaces, undergo renal filtration, enter hepatic pathways, or be taken up by receptor-bearing cells. Local concentration is not determined by total amount alone. Pharmacokinetic measurements require defined analytes, sampling windows, and models; pharmacodynamic readouts require separate validation. A longer measured signal can also reflect a fragment or assay artifact rather than intact active peptide.

Chemical modification, carriers, particles, depots, permeation strategies, fusion partners, and devices can alter protection, distribution, release, and manufacturability. They may also change potency, toxicity, immunogenicity, variability, or analytical requirements. A platform success with one sequence cannot be generalized without product-specific evidence. This page describes constraints and evaluation questions, not a route, device, formulation recipe, or personal-use method.